2013
A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.
Sandler A, Taylor M, Urba W, Omuro A, Anderson B, Hansen D, Fisher B, Claeys A, Greathouse A, McLean S, Karmali R. A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2518-2518. DOI: 10.1200/jco.2013.31.15_suppl.2518.Peer-Reviewed Original ResearchAdvanced solid tumorsCell lung cancerStable diseaseLung cancerSolid tumorsSquamous cell lung cancerSmall cell lung cancerAdequate organ functionGrade 3 fatigueCreatine kinase elevationSquamous cell carcinomaColon tumor xenograftsAnti-tumor effectsAnti-invasive propertiesPharmacokinetic samplingAdverse eventsQTc prolongationCell carcinomaTumor responseEGFR mutationsPIK3CA mutationsMalignant gliomasLung adenocarcinomaTumor assessmentCT scan
2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study